Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | CES1 | P23141 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | IDO1 | P14902 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29158557 | 0.91 | TSHR (0.53) | TSHRCYP2C19CYP1A2MAPTGAA | |
| SCHEMBL6932662 | 0.90 | CYP2C19 (0.61) | TSHRCYP2C19CYP1A2MAPTGAA | |
| SCHEMBL6647402 | 0.85 | TSHR (0.59) | TSHRCYP2C19CYP1A2MAPTGAA | |
| SCHEMBL28532343 | 0.83 | ALDH1A1 (0.60) | CYP2C19CYP1A2MAPTALDH1A1MEN1 | |
| SCHEMBL22408746 | 0.83 | CYP2C19 (0.54) | TSHRCYP2C19CYP1A2MAPTGAA | |
| SCHEMBL12179295 | 0.83 | CYP2C19 (0.54) | TSHRCYP2C19CYP1A2MAPTGAA | |
| SCHEMBL3014336 | 0.83 | CYP2C19 (0.54) | TSHRCYP2C19CYP1A2MAPTGAA | |
| SCHEMBL4833266 | 0.83 | GSK3B (0.58) | TSHRCYP2C19CYP1A2MAPTGAA | |
| SCHEMBL11373145 | 0.83 | CYP2C19 (0.54) | TSHRCYP2C19CYP1A2MAPTGAA | |
| SCHEMBL3083250 | 0.82 | CYP2C19 (0.57) | TSHRCYP2C19CYP1A2MAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116732114-A | Use of BsALS as catalyst in synthesis of o-hydroxy ketone compound and N-aryl hydroxamic acid | 西北大学 | 2023-09-12 | — | — | CN | disclosed |
| US-20230226093-A1 | ADENOSINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | BRII BIOSCIENCES, INC. | 2023-07-20 | — | — | US | disclosed |
| US-6794378-B2 | ANTIINFLAMMATORY AGENTS | AJINOMOTO CO., INC. (JP) | 2004-09-21 | — | — | US | disclosed |
| US-20020133005-A1 | Heterocyclic compounds and medical use thereof | AJINOMOTO CO., INC. (JP) | 2002-09-19 | — | — | US | disclosed |
| EP-1193255-A1 | HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF | Ajinomoto Co., Inc. (JP) | 2002-04-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226093-A1 | ADENOSINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | ADAR, ADA, ADORA2A | TSHR 4315/4885CYP2C19 585/4885CYP1A2 568/4885 |
| US-20020133005-A1 | Heterocyclic compounds and medical use thereof | NFKBIA, CHUK, RELA | TSHR 4622/4885CYP2C19 4099/4885CYP1A2 3947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.